Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

ABSTRACT: Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their enhanced CAR design. We performed the first phase 1/2 investigator-initiated trial evaluating escalating doses of third-generation CARTs (HD-CAR-1) targeting CD19 in patients with r/r CLL and B-cell lymphoma. CLL eligibility criteria were failure to two therapy lines including at least one pathway inhibitor and/or allogeneic hematopoietic cell transplantation. Nine heavily pretreated patients received HD-CAR-1 at dose levels ranging from 1 × 10⁶ to 200 × 10⁶ CART/m². In-house HD-CAR-1 manufacturing was successful for all patients. While neurotoxicity was absent, o

SUBMITTER: Derigs P 

PROVIDER: S-EPMC11519001 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature